APIActive Pharmaceutical Ingredient

An API is the substance in a pharmaceutical dosage form that exerts the pharmacological action — atorvastatin in Lipitor, paracetamol in Tylenol, semaglutide in Ozempic. The regulatory definition (ICH Q7 §1.1) is 'any substance or mixture of substances intended to be used in the manufacture of a drug product and that, when used in the production of a drug, becomes an active ingredient of the drug product'. The API is distinct from the drug product (the finished dosage form including excipients), the API intermediate (an in-process material that has undergone significant chemical change but is not yet the final API), and the starting material (the commercial chemical from which the API synthesis begins, regulated as a key input). Where 'API GMP' begins in a synthesis is itself a defined regulatory question — usually at the point of introduction of the Q11-defined 'starting material', the step at which all subsequent operations must be ICH Q7 compliant.

• Small-molecule chemical APIs — synthesised by chemistry (atorvastatin, paracetamol). ICH Q11 small-molecule annex applies; Q7 GMP.
• Biotech APIs — produced by living cells (monoclonal antibodies, recombinant proteins, insulin). ICH Q5A-E + Q6B + Q11 biotech annex; ICH Q7 + EU Annex 2 (manufacture of biological active substances).
• Cell and gene therapy products — viral vectors, CAR-T cells, gene-editing platforms. EU Annex 2A (cell therapy) and Annex 2B (gene therapy); FDA CBER oversight under Title 21 Subchapter F.
• Peptide APIs — synthetic (solid-phase synthesis) or recombinant. Both Q11 annexes can apply depending on route.
• Oligonucleotide APIs — antisense / siRNA / mRNA. Q11 with case-by-case interpretation; FDA / EMA have published technical guidance on starting-material and impurity expectations.
• Natural-product APIs — fermentation-derived (penicillins, statins) or plant-extracted (paclitaxel). Q11 botanical / fermentation guidance applies.
• Radiopharmaceutical APIs — short-half-life isotopes (FDG, Ga-68 ligands). 21 CFR 212 PET-specific GMP; conditional release built into the regulation.

An API moves through a defined regulatory lifecycle. Discovery: medicinal chemistry identifies the molecule and a lab-scale route. IND / preclinical: a gram-to-kilogram supply at Phase-1 GMP (per FDA's 2008 Phase-1 guidance, full ICH Q7 is not mandated but a defined subset is). Clinical scale-up: route optimisation, impurity profiling under ICH Q3A/B, scale increases to multi-kilogram and then to commercial scale (often a different route entirely, the 'commercial process' that lands in the NDA / MAA). Filing: the API section of the CMC dossier (eCTD Module 3 §3.2.S) carries the route, characterisation, control strategy, stability, and the manufacturer's GMP status. Commercial: PPQ at scale, continuous CPV, annual product review, and a controlled change-control regime governing every route change, supplier change and specification change through the product's commercial life.

ICH Q11 introduced a structured framework for designating the 'starting material' of an API synthesis — the step at which ICH Q7 GMP must begin. Filings propose the starting material; regulators challenge the proposal and frequently push the GMP boundary earlier in the synthesis (a 'late starting material' is a common pre-approval finding). The decision turns on: how many transformative steps remain to the API, how much of the impurity profile is shaped by post-starting-material chemistry, and whether the starting material is commercial-grade or bespoke. The boundary matters commercially — every step downstream of it is full GMP (qualified suppliers, validated cleaning, change-control, audit-ready) and every step upstream is conventional chemical manufacturing.

Every API has impurities: process-related (residual starting materials, by-products, reagents, residual solvents) and product-related (degradants formed during stability storage). The ICH impurity guidelines set the framework — Q3A (impurities in new drug substances), Q3B (impurities in new drug products), Q3C (residual solvents, with PDE limits), Q3D (elemental impurities, four classes with PDEs), and M7 (DNA-reactive / mutagenic impurities — Threshold of Toxicological Concern 1.5 µg/day, cohort-of-concern compounds with structure-specific Acceptable Intakes). Nitrosamine impurities (EMA Article 5(3), FDA 2021/2024 guidance) sit under M7 with extra source-4 risk assessment. The API specification carries impurity limits derived from these guidelines, and every commercial lot is tested against them on its Certificate of Analysis.

• Active-substance manufacturer (AS-Mfr) — the GMP-licensed plant making the API. Often in India, China, Italy, Germany, US, Switzerland, Spain, France.
• API distributor / repackager — under EU GMP Part II §17, distributors and repackagers of API are themselves GMP-regulated.
• Written confirmation — EU Falsified Medicines Directive (2011/62/EU) requires that every imported API has a written confirmation from the exporting country's competent authority that GMP equivalent to EU GMP was in force at the AS-Mfr.
• FDA Drug Master File (DMF) Type II — API manufacturers maintain a DMF that finished-dose manufacturers cross-reference in their NDA; the DMF carries confidential CMC information.
• CEP (Certificate of Suitability) — the European Pharmacopoeia equivalent of a DMF for monographed APIs; issued by EDQM after inspection.
• DSCSA / FMD — track-and-trace at the drug-product level; APIs are upstream of those programmes but increasingly subject to supplier-traceability requirements at finished-dose factories.

1. Starting-material designation accepted by one regulator and challenged by another — different boundaries in NDA vs MAA vs PMDA dossiers for the same product.
2. Q3D elemental impurity risk assessment outdated — the API supply changed, the supplier changed, but the risk assessment was not refreshed.
3. Nitrosamine source-4 (NDSRI) assessment skipped because the API has no obvious source-1/2/3 risk — source-4 still requires a documented assessment.
4. Stability under Q1A(R2) protocol followed for accelerated and long-term storage but no ongoing-stability commitment in place for commercial lots.
5. Phase-1 API manufactured under research-grade controls when even the abbreviated cGMP expectations of the 2008 guidance were not met.
6. Imported EU-bound API without the FMD written confirmation — the import block at the QP-release step.
7. API specification updated post-filing without a CBE-30 / Type IA variation — out-of-filing supply.

• API material master holds: monograph reference (USP / Ph.Eur. / JP / in-house), accepted specification version, every approved supplier with Q7 audit status, DMF / CEP reference, FMD written-confirmation expiry, current Q3C/Q3D/M7 risk assessments.
• Every commercial API lot has a CoA captured on receipt — automatic comparison against the approved specification, attribute-level pass/fail.
• Starting-material designation per route is held in the process master; route changes propose a new starting-material assessment that routes to regulatory.
• Impurity profile per lot trended over the rolling Stage-3 window — drift triggers a Q3 / M7 reassessment automatically.
• Stability programme per packaging configuration with ICH Q1A(R2) conditions; ongoing-stability commitment scheduled per Q1E.
• Audit, supplier-questionnaire and change-notification records linked to the AS-Mfr profile — a supplier going off the qualified list quarantines all in-flight POs.
• PPQ + CPV running on the API itself as well as on the finished drug product — both lifecycles share the trending engine.